- Home
- / Unicycive Therapeutics
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Unicycive Therapeutics financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Stock Price
$0.5
2024-10-29
Market Capitalization
$45.5 M
2024-10-29
Revenue
$675 K
FY, 2023
CreditSafe Score
?
Score changed on Jun 09, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2021 | FY, 2022 | FY, 2023 | FY, 2024 | FY, 2025 |
|---|---|---|---|---|---|
| Revenue | 951.0K | 675.0K | |||
| General and administrative expense | 2.9M | 6.6M | 8.5M | 12.1M | |
| Operating expense total | 19.0M | 21.4M | 32.1M | ||
| EBIT | (9.0M) | (18.1M) | (20.8M) | (32.1M) | |
| EBIT margin, % | -1898.2% | -3077.6% | |||
| Interest income | 615.0K | 1.3M | |||
| Interest expense | 82.0K | 12.0K | |||
| Net Income | (10.0M) | (18.1M) | (30.5M) | (36.7M) | |
| EPS | (1.2) | (1.3) | (0.6) | (1.7) |